Brief: Candel Therapeutics Presents Phase 3 Clinical Trial Of Can-2409
29/09/2025 13:47
Sept 29 (Reuters) - Candel Therapeutics Inc CADL.O: CANDEL THERAPEUTICS PRESENTS PHASE 3 CLINICAL TRIAL OF CAN-2409 IN LOCALIZED PROSTATE CANCER AT ASTRO 2025 Source text: ID:nGNX5Lvy86 Further company coverage: CADL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec